Healthcare Resource Utilization and Costs in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia Treated With Covalent Bruton's Tyrosine Kinase Inhibitors: Real-World Impact of Cardiovascular Adverse Events.

ABSTRACT:

Introduction

Although covalent Bruton's tyrosine kinase inhibitors (cBTKis) have transformed treatment of chronic lymphocytic leukemia and small lymphocytic leukemia (CLL/SLL), cBTKi-related cardiotoxicity is a known side effect. This real-world study evaluated incident cardiovascular adverse events (CVAE), healthcare resource utilization (HCRU), and costs among patients with CLL/SLL receiving cBTKis.

Methods

Adult patients with CLL/SLL who initiated ibrutinib or acalabrutinib treatment (index date) between 2020 and 2023 were identified using US claims data and followed up to 36 months post-index. Incident CVAEs (not present pre-index) were assessed during cBTKi treatment and patients were stratified by CVAE status. HCRU and costs were evaluated per 1000 patient-months (PPPM

SUBMITTER: Obeng-Kusi M 

PROVIDER: S-EPMC12719235 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature